Project Grant R44AI095159

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $2.3 million Project Grant to the University of California, Davis to fund research targeting CD4 T follicular helper cells for enhancing HIV vaccine-induced humoral immunity. The two-year award, issued on May 12, 2021 under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support preclinical studies in rhesus macaques to better understand the immunological mechanisms...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded J. David Gladstone Institutes a $3.56 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 26, 2025, for research extending through August 31, 2029. The project focuses on developing an innovative hybrid messenger RNA (mRNA) vaccine technology that combines features of mRNA and protein nanoparticle platforms to advance HIV-1 vaccine...

Federal Project Grant Award Summary Duke University's Office of Research Administration received a $208,875 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2028. The grant supports research and development of a multivalent messenger ribonucleic acid (mRNA) HIV vaccine designed to elicit broadly neutralizing antibodies (BNAbs) targeting conserved...

Grant Award Summary Duke University received a $791,661 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through July 31, 2030. The award supports research focused on developing an HIV-1 vaccine utilizing integrase-defective lentiviral vectors (IDLVs) to deliver HIV and SIV antigens. The research aims to optimize vaccine delivery platforms and multi-antigen strategies...

Federal Grant Award Summary Gateway Bio Inc. received a $606,346 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of September 1, 2025 through August 31, 2026. The award supports the development of a novel stealth lipid formulation to advance HIV vaccine research. Specifically, Gateway Bio will develop a poly(oligoethylene glycol) methyl ether methacrylate (POEGMA)-based...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $253,256 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to establish preclinical research platforms for engineered B cell therapies targeting HIV. The award, effective June 1, 2026 through May 31, 2028, supports two primary research objectives: (1) demonstrating whether immunoglobulin heavy chain...

Federal Project Grant Award Summary Emory University received a $910K Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 5, 2026 through April 30, 2031. The award supports the development of an HIV vaccination strategy utilizing DNA-lipid nanoparticle (DNA-LNP) technology designed to induce strong and durable cellular and humoral immune responses. The research aims to...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pennsylvania a $891,410 Project Grant on August 14, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a personalized therapeutic HIV vaccine strategy. The research, scheduled for completion by July 31, 2030, focuses on designing individualized messenger RNA (mRNA)-lipid nanoparticle (LNP) delivered envelope immunogens to boost...

Federal Grant Award Summary Loyola University of Chicago's Health Sciences Campus received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2027. The award supports the development of a novel mucosal cytotoxic T lymphocyte (CTL)-based human immunodeficiency virus (HIV) vaccine utilizing bovine papillomavirus-like particles (BPV...

Federal Project Grant Award Summary Tendel Therapies Inc. received a $999,991 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 13, 2025, with a completion date of July 31, 2028. The award supports the development and optimization of BSAB-98, a bispecific antibody (BSAB) therapeutic agent designed to deplete CCR5-expressing cells that form a critical component of the HIV...